Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rivastigmine
Drug ID BADD_D01955
Description Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Indications and Usage For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Marketing Status approved; investigational
ATC Code N06DA03
DrugBank ID DB00989
KEGG ID D03822
MeSH ID D000068836
PubChem ID 77991
TTD Drug ID D0WY5Q
NDC Product Code 16714-117; 70710-1198; 72855-101; 0781-7304; 65372-1153; 82245-0107; 51956-0001; 51956-0002; 51991-898; 65162-826; 72855-102; 49706-1825; 0078-0503; 63629-2065; 65162-749; 65162-825; 0378-9072; 0781-7309; 12651-118; 64552-4021; 65015-819; 0078-0501; 63629-8846; 0378-9071; 70710-1196; 16714-115; 63629-2066; 50379-0014; 65862-982; 72855-100; 51956-0003; 51991-897; 51991-899; 0781-7313; 63629-2064; 0378-9070; 0078-0502; 16714-116; 63629-8807; 70710-1197
UNII PKI06M3IW0
Synonyms Rivastigmine | (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate | RivastigmineTartrate | Rivastigmine Hydrogen Tartrate | Hydrogen Tartrate, Rivastigmine | Tartrate, Rivastigmine Hydrogen | Exelon | ENA 713 | 713, ENA | SDZ ENA 713 | 713, SDZ ENA | ENA 713, SDZ | ENA-713 | ENA713
Chemical Information
Molecular Formula C14H22N2O2
CAS Registry Number 123441-03-2
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Seizure17.12.03.0010.002710%
Serotonin syndrome15.05.04.016; 12.03.01.041; 17.05.02.0040.001084%Not Available
Sinus bradycardia02.03.03.0090.002168%
Skin cancer23.08.02.002; 16.03.02.0020.000542%Not Available
Skin disorder23.03.03.0070.001084%Not Available
Skin exfoliation23.03.07.0030.001192%Not Available
Skin irritation23.03.04.0090.004878%Not Available
Skin reaction10.01.03.019; 23.03.03.0130.002276%Not Available
Sleep apnoea syndrome22.02.01.013; 19.02.05.002; 17.15.05.0010.000542%
Sleep disorder19.02.04.0010.001355%Not Available
Somnolence19.02.05.003; 17.02.04.0060.007750%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.004878%Not Available
Status epilepticus17.12.03.0050.000542%Not Available
Subarachnoid haemorrhage24.07.04.004; 12.01.10.011; 17.08.01.0100.000542%Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.006775%
Tachycardia02.03.02.007--Not Available
Tachypnoea22.02.01.0140.001355%Not Available
Tension19.06.02.0050.000813%Not Available
Thinking abnormal19.10.03.001; 17.02.05.0230.002927%Not Available
Thyroid disorder05.02.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.0020.001843%
Transient ischaemic attack24.04.06.005; 17.08.04.0010.001084%
Tremor17.01.06.0020.005907%
Trigeminal neuralgia17.04.08.001--Not Available
Unresponsive to stimuli17.02.05.0310.000813%Not Available
Urinary incontinence20.02.02.010; 17.05.01.0080.000813%
Urinary retention20.02.02.0110.001084%
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Ventricular tachycardia02.03.04.010--
The 8th Page    First    Pre   8 9 10 11    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene